StockData
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. (SANA) company profile

SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.85−0.03 (-1.60%)

Close on Nov 18, 2026Market cap $553.82MP/E –Yield –

About Sana Biotechnology

Biological Products, (No Diagnostic Substances), SIC 2836

This biotechnology company develops ex vivo and in vivo cell engineering platforms to create therapies for severe medical conditions. Its research focuses on treatments for type 1 diabetes, B-cell malignancies, and autoimmune disorders. The firm's primary product candidates include SC451, an engineered stem cell-derived pancreatic islet cell therapy designed to restore normal glucose levels without immunosuppression, and SG293, an in vivo CAR T therapy delivered via fusosomes to deplete disease-causing B cells. These therapeutic candidates target patients diagnosed with insulin-dependent diabetes, hematologic cancers, and B-cell-driven autoimmune diseases.

The company maintains worldwide commercial rights to its pipeline and utilizes external contract development and manufacturing organizations alongside an internal master cell bank. Clinical evaluation includes an investigator-sponsored trial at Uppsala University Hospital, and regulatory discussions span multiple international jurisdictions. The excerpt does not disclose the company's headquarters location or specific facility figures.

Summary of the business section of Sana Biotechnology's latest annual report, written by StockData.

Company profile

Company

Legal name
Sana Biotechnology, Inc.
Headquarters
Seattle, WA
Address
188 East Blaine Street, Suite 350
Phone
(206) 701-7914
Website
sana.com
Employees
142, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Seattle, Washington

Stock & identifiers

Ticker
SANA
Exchange
Nasdaq
IPO date
Feb 5, 2021
Shares outstanding
299M, Aug 3, 2026
Public float
$295.10M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1770121
CUSIP
799566104
ISIN
US7995661045
FIGI
BBG00N5BMH61
Share class FIGI
BBG00N5BMH70
EIN
83-1381173

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Steve HarrPresident & CEO, Director8,960,751
Dhavalkumar Dhirajlal PatelEVP, Chief Scientific Officer183,352
Susan D. WyrickSee Remarks197,241
Brian PiperEVP, Chief Financial Officer–
Bernard J. CassidyEVP & General Counsel112,990
Hans Edgar BishopDirector5,863,480
Robert NelsenDirector10,681,240
Michelle SeitzDirector–
Richard MulliganDirector2,698,121
Alise ReicinDirector–
Patrick Y. YangDirector149,250
Joshua H. BilenkerDirector20,000
Robert L. RosielloDirector–
Mary Agnes WilderotterDirector7,106

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Steven D. Harr, M.D.
President, Chief Executive Officer, and Director
$696.14K$425.00K$1.33M$450.37K$4.00K$2.90M-67%
Bernard J. Cassidy
Former Executive Vice President, General Counsel, and Corporate Secretary
$404.03K$136.00K$424.80K–$51.28K$1.02M-57%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 5, 2021
Offer price
$25.00
Securities offered
23,500,000
Gross proceeds
$587.50M
Exchange
Nasdaq
First trading day
Feb 4, 2021
First-day close
$35.10+40.4%
Lock-up ends (est.)
Aug 3, 2021

“Our initial public offering price is $25.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 142 employees, 104 of whom were primarily engaged in research and development activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?